1207976-38-2

Upstream product

• 1207976-33-7 benzhydryl (2S,4aS,6aS,6bR,8aR,12aS,12bR,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10,13-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylate 
• 908093-98-1 diazodiphenylmethane 
• 471-53-4 enoxolone 

Downstream Products

• 1207976-44-0 (3α,18β,20β)-3-amino-11-oxo-olean-12-en-29-oic acid diphenylmethyl ester 
• 1207976-43-9 (3β,18β,20β)-3-amino-11-oxo-olean-12-en-29-oic acid diphenylmethyl ester 
• 1360075-39-3 (5aR,7aR,7bS,9aS,12S,13aR,15aR,15bS)-2,3,4,5,5a,6,7,7a,7b,8,9,9a,10,11,12,13,13a,15,15a,15b-eicosahydro-5,5,7a,7b,9a,12,15b-heptamethyl-3,15-dioxo-1H-chryseno[2,1-c]azepine-12-carboxylic acid diphenylmethyl ester 

Relevant academic research and scientific papers

NOVEL TRITERPENE DERIVATIVES

The present invention encompasses compounds of general formula (I) wherein R11a to R30 and X are defined as in claim 1, which are suitable for the treatment of and/or prevention of chronic inflammatory diseases, autoimmune diseases,

Synthesis of glycyrrhetinic acid derivatives for the treatment of metabolic diseases

The effect of glycyrrhetinic acid (GA) and GA-derivatives towards 11β-hydroxysteroid dehydrogenase (11β-HSD) was investigated. Novel compounds with modifications at positions C-3, C-11 and C-29 of the GA skeleton were prepared. Single crystal X-ray diffraction data of selected substances are reported and discussed.